

claims of 9,139,153 for comparison

WHAT IS CLAIMED IS

1. A non-naturally occurring gene therapy vector for cell-specific delivery of nucleic acid to a target cell, comprising a recombinant core and a non-naturally occurring functional surface moiety,

5 wherein said core comprises a nucleic acid molecule, wherein at least one expression product of said vector is a therapeutic nucleic acid, peptide or protein; and

 wherein said functional surface moiety comprises at least one functional element selected from the group consisting of an immuno-protective element, a targeting element, and a cell-entry element,

10 whereby the vehicle is capable of specifically binding to and delivering said core into a target cell.
2. The vector according to claim 1, wherein said core further comprises at least one viral capsid protein.
3. The vector according to claim 1, wherein said functional surface moiety comprises an immunoprotective element.
4. The vector according to claim 1, wherein said functional surface

20 moiety comprises a targeting element.
5. The vector according to claim 1, wherein said functional surface moiety comprises a cell-entry element.

6. The vector according to claim 1, wherein said functional surface moiety comprises an immunoprotective element, a targeting element, and a cell-entry element.

5 7. The vector according to claim 3, wherein said immunoprotective element is a synthetic polymer moiety.

8. The vector according to claim 4, wherein said targeting moiety binds to a receptor that is more highly expressed in diseased cells than in normal cells.

10

9. The vector according to claim 8, wherein said targeting moiety is a peptide or peptidomimetic ligand for a cell surface receptor.

100T80-EST-2260
0937153-08100
15 10. The vector according to claim 5, wherein said cell-entry element is a membrane-destabilizing moiety.

11. The vector according to claim 10, wherein said membrane-destabilizing moiety comprises an amphiphilic α -helix.

20 12. The vector according to claim 10, wherein said membrane-destabilizing moiety comprises a copolymer of glutamic acid with leucine.

13. The vector according to claim 11, wherein said amphiphilic α -helix is derived from the C-terminal domain of a viral *env* protein.

14. The vector according to claim 13, wherein C-terminal domain is the C-terminal domain of the Moloney leukemia virus *env* protein.

15. The vector according to claim 14, wherein said C-terminal domain
5 comprises amino acids 598-616 of the Moloney leukemia virus *env* protein.

16. The vector according to claim 7, wherein said synthetic polymer component comprises a poly(ethyleneglycol).

10 17. The vector according to claim 7, wherein said synthetic polymer component comprises a copolymer of glutamic acid with leucine.

18. A method of treating a disease in a patient, comprising administering
15 to said patient a therapeutically effective amount of a vector according to claim 1.